Suven Pharmaceuticals's target Rs 800: IIFL Securities's Top Stock to Buy Today

On June 27, IIFL Securities issued a buy recommendation for Suven Pharmaceuticals at its current market price of Rs 768. The brokerage firm believes that the company has a strong product pipeline and is well-positioned to benefit from the growing demand for generic drugs. IIFL Securities has set a target price of Rs 800 for Suven Pharmaceuticals, representing a potential upside of over 4% from the current market price.

About Suven Pharmaceuticals:

Suven Pharmaceuticals Limited is a Hyderabad-based pharmaceutical company listed on the National Stock Exchange (NSE). It focuses on the discovery, development, and commercialization of proprietary novel drug molecules in the areas of central nervous system (CNS) disorders, cancer, and metabolic disorders. The company has a rich pipeline of drug candidates in various stages of development and has successfully out-licensed several molecules to global pharmaceutical companies. Suven Pharmaceuticals is committed to innovation and has built a strong R&D infrastructure with a dedicated team of scientists.

52 Week Price Trend:

Suven Pharmaceuticals, with a current market price (CMP) of Rs 768, has been trading near its 52-week high of Rs 768. This indicates a strong upward trend in the stock price. However, it is important to note that the stock has also seen significant volatility in the past year, with its 52-week low reaching Rs 375. Investors should carefully consider the company's financials and market conditions before making any investment decisions.

Stratzy's MOST Analysis:

Stratzy's MOST framework has rated SUVENPHAR AA, indicating low fundamental risks. This rating is based on a comprehensive assessment of the company's Management (AA), Outlook (AA), Safety (AA), and Trend (AA) pillars. The strong scores across all pillars suggest that SUVENPHAR has a robust management team, positive growth prospects, a solid financial position, and a favorable industry trend. This overall rating of AA indicates that SUVENPHAR is a low-risk investment with strong fundamentals.

Company's Fundamentals:

Suven Pharmaceuticals (SUVENPHAR) is currently trading at a stock Price-to-Earnings (PE) ratio of 46.03. This value represents the number of years it would take for an investor to recoup their initial investment based on the current earnings of the company. Additionally, the Price-to-Book (PB) ratio of 8.82 indicates that investors are paying 8.82 times the book value of the company's assets for each share. Finally, SUVENPHAR offers a dividend yield of 0.15%, meaning that investors receive a 0.15% return on their investment in the form of dividends each year.

Fundamental and Technical information provided in this blog were last updated on 27 Jun, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.